INTRODUCTION {#s1}
============

Epithelial cells (ECs) are the first line of defense against airborne pathogens and allergens. ECs modulate immune responses by regulating the expression of different pattern recognition receptors and *via* their own ability to produce a plethora of cytokines and chemokines. Furthermore, it is well established that the cross-talk between ECs and dendritic cells (DCs) is very important in orchestrating immune responses to airborne antigens. In this context, ECs have been shown to directly and indirectly modulate T cell responses \[[@R1], [@R2]\]. In particular, airway ECs can influence T cell activation and differentiation by increasing the recruitment, maturation, and activation of DCs through the secretion of diverse chemokines \[[@R3]--[@R5]\] and cytokines \[[@R6], [@R7]\]. For example, murine colonic \[[@R8]\] and lung \[[@R9], [@R10]\] ECs are able to inhibit antigen presenting cell-induced T cell proliferation. This effect appears to be cell-cell contact-dependent \[[@R8]--[@R10]\], and was found to be attenuated by pre-treatment of ECs with IL-4 \[[@R10]\] or after viral infection \[[@R9]\]. In addition, it has been suggested that direct contact between ECs and DCs is essential to inhibit *in vitro* T cell responses against allergens \[[@R11]\]. However, despite some evidence suggesting a role for TGF-β in decreasing T cell proliferation to some extent, the exact mechanism underlying such EC-mediated suppression of T cell responses has remained elusive \[[@R9]\].

Tryptophan (TRP) is an essential amino acid for the synthesis of proteins and neurotransmitters as well as for cell growth and function \[[@R12]\]. In mammals, the primary route of TRP degradation into kynurenines (KYNs) is controlled by extra-hepatic indoleamine 2,3- dioxygenase (IDO) and hepatic tryptophan 2,3-dioxygenase. There are two IDO isoforms, IDO1 and IDO2 \[[@R13]--[@R15]\], and these isozymes exhibit different expression patterns and molecular regulation \[[@R12], [@R15], [@R16]\]. However, the function of IDO1 (herein referred to as IDO) has been more extensively analyzed and was shown to have diverse immune-regulatory properties \[[@R17], [@R18]\]. TRP depletion as well as TRP-derived metabolites can impact T cell activation by inducing apoptosis, activating the stress-response kinase GCN2, or promoting tolerance through activation of the aryl-hydrocarbon receptor \[[@R19], [@R20]\]. DCs express high levels of IDO in response to different stimuli, including cytokines such as type-I and type-II IFNs, co-stimulatory molecules, and TLRs \[[@R21]\]. IDO is highly expressed in the immune cells; however, non-immune cells, including ECs, have also been shown to express functional IDO \[[@R22]\]. Previous work has shown an increase in IDO activity and expression (at the mRNA level) in human cervical ECs (HeLa cells) after stimulation with IFN-γ \[[@R23], [@R24]\]. This effect was further enhanced in the presence of IL-1 or TNF-α, but not in response to LPS stimulation. Furthermore, it was demonstrated that diverse epithelial carcinoma cell lines \[[@R25]--[@R27]\] and primary ECs \[[@R28], [@R29]\] express IDO after IFN-γ treatment. In addition, functional IDO expression has been reported to be high in the lung \[[@R30]\]. More recently, it was demonstrated that *Aspergillus fumigatus* spores induced the up-regulation of IDO in corneal ECs, suggesting the involvement of IDO from ECs in the immune responses against fungal infections \[[@R31]\].

The aim of this study was to investigate the regulation of IDO expression and activity in airway cancerous and non-cancerous ECs in response to TLR agonists and allergen extracts; and to investigate the potential role of EC-derived IDO in the regulation of T cell activation.

RESULTS {#s2}
=======

Human airway ECs inhibit T cell activation in a contact-independent manner {#s2_1}
--------------------------------------------------------------------------

Previous studies have demonstrated that murine ECs are able to inhibit T cell proliferation \[[@R8]--[@R10]\]. Here, we first evaluated whether human airway ECs can inhibit T cell proliferation.

ECs cultured on the apical side of a transwell membrane, were co-cultured with PBMCs (with no cell-cell contact) followed by stimulation with either PPD or anti-CD3 and CD28 Abs; and T cell proliferation was quantified after 3-6 days. The presence of ECs significantly suppressed PBMC proliferation (Figure [1A](#F1){ref-type="fig"}) and IFN-γ production (Figure [1B](#F1){ref-type="fig"}). We also performed the same experiments using a co-culture of DCs and purified T cells, which showed a similar level of suppression of T cell proliferation in the presence of ECs (data not shown).

![Inhibition of PBMC proliferation and IFN-γ production by human airway epithelial cells (ECs)\
**A.** Airway ECs (Calu-3) were co-cultured with PBMCs stimulated with 5 μg/ml of tuberculin purified protein derivate (PPD) without cell-cell contact (carried out in transwells^®^ with a 0.4-μm pore size). After six days, cell proliferation was assessed. **B.** IFN-γ concentration in culture supernatants. usPBMC= unstimulated PBMC, Data show mean ± SEM from three independent experiments. \*\*\*\**p* \< 0.0001.](oncotarget-07-57606-g001){#F1}

Stimulation of ECs with TLR3 and TLR4 ligands ameliorates their ability in suppressing T cell activation {#s2_2}
--------------------------------------------------------------------------------------------------------

We next investigated whether TLR agonists, simulating bacterial or viral infections, modulated the observed inhibitory effect of airway ECs on T cell activation. Therefore, we exposed airway ECs to TLR4 or TLR3 ligands (LPS and polyI:C, respectively) followed by their co-culture with anti-CD3/CD28-stimulated PBMCs. After three days, the cells were collected for a BrdU proliferation assay and the supernatant was collected for cytokine analysis. LPS and polyI:C treatment of ECs led to a clear reduction in their ability to suppress T cell proliferation compared with the control (Figure [2A](#F2){ref-type="fig"}). The degree of this effect correlated with the level of IFN-γ production, which showed a significant increase in response to LPS stimulation after 24 h and 48 h, and was also slightly enhanced in response to polyI:C, although this change was not statistically significant (Figure [2B](#F2){ref-type="fig"}). These findings suggest that the ability of ECs to regulate T cell activation could be significantly compromised following bacterial or viral infections.

![Influence of TLR-activated airway epithelial cells (ECs) on PBMC proliferation\
**A.** Human airway ECs (Calu-3) were co-cultured with PBMCs stimulated with 2 μg/ml of anti-CD3 and anti-CD28 in the presence of 10 μg/ml of LPS or polyribocytidylic acid (PolyI:C). After three days, proliferation was assessed. **B.** IFN-γ production in culture supernatants. Data show mean ± SEM from three independent experiments. us=unstimulated\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, ns, not significant.](oncotarget-07-57606-g002){#F2}

TLR4 stimulation down-regulates IDO in human airway ECs without compromising cell viability {#s2_3}
-------------------------------------------------------------------------------------------

To test the hypothesis that the inhibition of T cell proliferation by ECs could be mediated by IDO, we first investigated the levels of IDO expression in ECs before and after stimulation with the TLR4 ligand LPS. Initially, we used the Calu-3 cell line as a model for human ECs. These cells were incubated with increasing concentration of LPS (from *Escherichia coli*) for 24 h, and IDO activity and expression were assessed. Significant down-regulation in IDO activity was observed (Figure [3A](#F3){ref-type="fig"}) in response to LPS stimulation. This reduction in IDO activity was accompanied by suppression in IDO1 protein (Figure [3B](#F3){ref-type="fig"}) and gene (Figure [3C](#F3){ref-type="fig"}) expression. LPS from *Salmonella minnesota* had the same effect on IDO activity (data not shown). To determine whether cell death contributed to the observed reduction in IDO activity, we measured the viability of ECs after LPS stimulation using AlamarBlue and LIVE/DEAD staining. The data showed comparable EC viability before and after LPS stimulation (Figure [3D](#F3){ref-type="fig"}), indicating that the substantial reduction of IDO expression was not associated with cellular death. The same pattern of a reduction in IDO activity in response to LPS was also observed in human primary ECs as well as in a non-cancerous epithelial cell line (BEAS-2B), highlighting the conserved nature of IDO regulation by LPS (Figure [4](#F4){ref-type="fig"}).

![Down-regulation of indoleamine 2,3-dioxygenase (IDO) in response to LPS stimulation in human airway epithelial cells (ECs)\
**A.** Human airway ECs were incubated with increasing concentration of *E. coli* LPS for 24 h and IDO activity was assessed (*n* = 5). **B.** and **C.** IDO1 protein and gene expression in airway ECs stimulated with 2 μg/ml of LPS for 24 h, respectively (*n* = 3). **D.** LIVE/DEAD staining of airway ECs stimulated with LPS (10 μg/ml) for 24 h. Cells treated with 4% formaldehyde were used as a control. **E.** The fluorescence quantification of the LIVE/DEAD staining expressed as percentage of live cells (*n* = 2). **F.** AlamarBlue fluorescence readouts of airway ECs stimulated with increasing concentrations of LPS for 24 h; cells treated with 4% formaldehyde were used as a control (*n* = 4). Ctl=control Data represent the mean values ± SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\*\**p* \< 0.0001.](oncotarget-07-57606-g003){#F3}

![Down-regulation of indoleamine 2,3-dioxygenase (IDO) in response to LPS stimulation in human primary bronchial epithelial cells (HBECs) and cell lines\
**A.** and **B.** primary HBECs (*n* = 3) and HBEC line (BEAS-2B, *n* = 5) were incubated with increasing concentrations of *E. coli* LPS for 24 h, respectively, and IDO activity was assessed. (C and D) *IDO1* gene expression in response to stimulation with 2 μg/ml and 0.1 μg/ml of LPS in primary HBECs and BEAS-2B, respectively (*n* = 3). Data represent the mean values ± SEM. \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](oncotarget-07-57606-g004){#F4}

Diverse TLR ligands and allergen extracts decrease IDO activity and expression in human airway ECs {#s2_4}
--------------------------------------------------------------------------------------------------

To verify whether IDO downregulation is only observed in response to LPS, we next sought to determine the impact of other TLR ligands as well as different allergen extracts on IDO activity in human airway ECs. ECs were incubated for 24 h with 10 μg/ml of various TLR ligands or allergen extracts. As shown in Figure [5](#F5){ref-type="fig"}, TLR3 (polyI:C), TLR2/6 (FSL-1), and TLR9 (CpG) engagement markedly inhibited IDO activity. However, TLR7 and TLR1/2 ligation with imiquimod and a synthetic triacylated lipopeptide (Pam3CSK4) respectively did not affect IDO activity levels in ECs (data not shown). Furthermore, we found significant inhibition of IDO activity in response to different allergen extracts, including Bermuda grass pollen (BGP), peanut (PEA), German cockroach (GC), house dust mite (HDM) and its purified allergen Der p 1 (Figure [5A](#F5){ref-type="fig"}). The down-regulation of IDO activity was also observed in primary ECs in response to LPS, CpG, and different allergen extracts (Figure [5B](#F5){ref-type="fig"}). To examine whether the suppression in IDO activity was reflected in its expression at the protein level, we also quantified IDO1 protein expression levels in ECs before and after TLR ligation using western blotting. These experiments showed a marked reduction in IDO1 protein expression in TLR-stimulated ECs compared to unstimulated cells (Figure [5C](#F5){ref-type="fig"}).

![Diverse TLR ligands and allergen extracts decreased indoleamine 2,3-dioxygenase (IDO) expression in human airway epithelial cells (ECs)\
**A.** Airway ECs (Calu-3) were incubated with 10 μg/ml of different TLR ligands and allergen extracts for 24 h (n ≥ 3). **B.** Primary human bronchial ECs were incubated with 2 μg/ml LPS, 10 μg/ml CpG, and 10 μg/ml allergen extracts (*n* = 3). **C.** Calu-3 ECs were treated with 10 μg/ml LPS, 10 g/ml polyribocytidylic acid (PolyI:C), or 10 g/ml CpG for 24 h, and IDO1 protein levels were assessed in cell lysates by western blot analysis; GAPDH was used as a control (*n* = 3). Observed band sizes were 45 kDa for IDO1 and 36 kDa for GAPDH, as predicted. HDM, house dust mite; BGP, Bermuda grass pollen; PEA, peanut; GC, German cockroach. Data represent the mean values ± SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](oncotarget-07-57606-g005){#F5}

IDO contributes to the airway ECs-mediated suppression of T cell activation {#s2_5}
---------------------------------------------------------------------------

Previous findings have suggested a role for EC-produced TGF-β in modulating T cell proliferation \[[@R9]\]. However, the exact mechanism by which ECs inhibit T cell proliferation remains unclear. We therefore examined the potential role of IDO in mediating the inhibitory effect of ECs on T cells. First, we attempted to block IDO activity in ECs/PBMCs co-cultures using 1-methyl tryptophan, an IDO-inhibitor. However, given the direct effect of 1-methyl tryptophan on PBMCs leading to suppression of their proliferation (data not shown), we decided to directly target IDO activity in ECs. Thus, we generated IDO^low^-ECs by knocking down the *IDO1* gene in ECs using small interfering RNA (siRNA), so that only IDO activity was suppressed in ECs. As shown in Figure [6A](#F6){ref-type="fig"}, there was a significant decrease in IDO activity and *IDO1* mRNA levels after gene silencing (i.e., IDO^low^) compared with the control cells that expressed high levels of IDO. Subsequently, we co-cultured the IDO^low^-ECs with anti-CD3-activated PBMCs, and proliferation was assessed three days later. Figure [6B](#F6){ref-type="fig"} shows that, as expected, IDO-sufficient ECs significantly inhibited T cell proliferation, and this effect was significantly reduced after silencing IDO. We also investigated cytokine production after 24 h and 48 h. As expected, we observed a significant reduction in IFN-γ production in the presence of ECs and a partial reconstitution in IFN-γ levels in the presence of IDO^low^-ECs compared with the control cells (Figure [6C](#F6){ref-type="fig"}). Collectively, these results demonstrated the important role of IDO produced by ECs for the inhibition of T cell activation.

![Role of indoleamine 2,3-dioxygenase (IDO)-expressing airway epithelial cells (ECs) on inhibition of PBMCs activation\
**A.** Human airway ECs were transfected for 6 h with 50 nM of IDO1 small interfering RNA (siRNA) using a non-targeting siRNA as a negative control. The efficiency of IDO downregulation after transfection was assessed by evaluation of IDO activity and *IDO1* mRNA expression (*n* = 3). **B.** Control ECs (i.e., IDO^high^) and IDO^low^-ECs were co-cultured with anti-CD3-activated PBMCs. After three days, proliferation was assessed (*n* = 4). **C.** IFN-γ levels in the culture supernatants were quantified after 24 h and 48 h (*n* = 3). Data represent the mean values ± SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001; ns, not significant.](oncotarget-07-57606-g006){#F6}

DISCUSSION {#s3}
==========

ECs are one of the main cellular components of the innate immune system, which provide primary protection against airborne pathogens and allergens. Previous studies have shown that ECs can directly regulate conventional and unconventional T cell responses \[[@R8], [@R9], [@R32], [@R33]\]; however, the molecular basis of such regulation has remained elusive. We hypothesized that airway ECs modulate human T cell responses *via* expression of IDO. Our data showed that airway ECs could suppress antigen-specific and non-specific T cell activation (i.e., T cell proliferation and IFN-γ production). Furthermore, the levels of T cell activation were partially recovered when ECs were exposed to different TLR agonists as mimics for bacterial and viral infections. Such reduction in the immune-suppressive effect of ECs after stimulation with bacterial and viral products could be crucial for facilitating the development of appropriate inflammatory responses for containing the infection.

IDO is the TRP-depleting enzyme in the KYN pathway and has been extensively associated with modulating immune responses. DCs are one of the main producers of IDO-derived metabolites in the immune system \[[@R17], [@R18]\]; however, over the last decade ECs have also emerged as key players in modulating immune responses in the airways. Upon stimulation with allergens, airway ECs are able to produce a wide range of innate mediators that can activate other immune cells, including DCs, basophils and innate lymphoid cells. In addition, ECs express functional IDO after stimulation with pro-inflammatory cytokines such as IFN-γ and TNF-α \[[@R23], [@R24], [@R26]--[@R29]\].

It is widely recognised that IDO is constitutively expressed by many tumors as well as by infiltrating leucocytes present within the tumor microenvironment \[[@R34]--[@R36]\]. IDO is enzymatically active in human cancerous cell lines and creates an immunosuppressive microenvironment *via* TRP depletion and by formation of immunosuppressive IDO metabolites \[[@R37], [@R38]\]. In tumor state, high IDO expression and activity provides systemic tolerance *via* inhibition of the effector T cell infiltration \[[@R34], [@R39]\] and induction of Treg formation \[[@R40]\]. In addition, IDO could promote tumor cell survival and motility *via* production of endogeneuos KYN that drive the activation of aryl hydrocarbon receptor in cancer cells \[[@R16]\]. It has been reported that induction of IDO *via* IFN-γ provides anti-tumor effector mechanism in diverse human cancer cell lines including epithelial cell lines through the inhibition of their proliferation *via* TRP starvation \[[@R41]\]. Taken together, it is evident that elevated level of IDO in tumor environment could provide local and systemic immune suppression to facilitate immune escape by cancer cells \[[@R35]\]. Here in this study, we show for the first time that human airway ECs constitutively express IDO under resting conditions and critically there is significant down-regulation of IDO activity in both primary ECs and the cell lines in response to a wide range of TLR ligands and allergen extracts. Although the basal level of KYN production by primary human bronchial epithelial cells was lower (\~3-6 μM) than that in BEAS-2B or Calu-3 cell lines (\~20-40 μM) both cell types were similarly susceptible to stimulation with TLR ligands and allergens. Previous studies have suggested nitric oxide (NO) can inhibit IDO activity and expression \[[@R26], [@R42]\] most likely through post-translational regulation leading to proteasomal degradation of IDO rather than transcriptional regulation \[[@R26]\]. Down-regulation in IDO protein levels has also been observed in DCs through IL-6 mediated proteasomal degradation \[[@R43], [@R44]\]. Since our data show significant transcriptional changes in IDO levels in ECs, hence it is reasonable to assume that the observed transcriptional changes in IDO in our experiments are unlikely to be due to changes in IL-6 or NO levels, and rather involve activation of intracellular signaling pathways that ultimately modulate IDO gene expression. Indeed this is in line with our observation showing no changes in IL-6 levels in all our experimental conditions (data not shown).

Interestingly, the down-regulation of IDO in response to these stimuli in ECs is in contrast to the responses previously observed in DCs and macrophages \[[@R21], [@R45], [@R46]\], in which IDO activity is generally up-regulated. This finding thus highlights the complexity of IDO regulation and fundamental differences in its activity between different cell types. It is reasonable to suggest that the constitutive expression of IDO by ECs under steady-state conditions is associated with their ability to suppress unwanted immune reactions and to maintain immune homeostasis in the airways. In the context of cancerous cell lines, the high level of IDO activity contributes to the immunosuppressive tumor environment. However, after encountering pathogens (i.e., TLR engagement) and/or allergens (i.e., TLR or C-type lectin engagement), this regulatory mechanism could be disrupted through down-regulation of IDO activity, which in turn could lead to increased T cell activity and subsequent immune responses to combat the infection.

Previous studies have shown the importance of IDO from ECs during viral, bacterial, and parasite infections \[[@R26], [@R28], [@R31], [@R47]--[@R53]\]. Moreover, increased susceptibility to infection has been associated with the development of asthma-related diseases \[[@R54]\]. Accordingly, it would be interesting to explore the role of IDO and specific IDO-derived metabolites from airway ECs in modulating other immune and non-immune cells in the context of respiratory infection.

We further evaluated the direct role of IDO in ECs in modulating T cell activation by generating IDO^low^-ECs using gene silencing. We found that knocking down IDO activity in ECs significantly reduced their ability to suppress T cell proliferation and IFN-γ production, suggesting an important role for IDO in this process. This effect is likely to be driven by a reduction in the level of IDO metabolites such as KYN and 3-HAA which are thought to drive most of the IDO-immune-suppressive effects \[[@R20], [@R55]--[@R60]\] however the exact mechanism is yet to be elucidated. It is also important to emphasize that the effects of IDO metabolites produced by ECs may not be limited to T cells, and might also modulate the function of other immune cells (e.g. basophils, and mast cells), broadening their overall immune modulatory effect. Future work should explore such possibilities.

In conclusion, our results underline the important role of airway ECs in controlling immune responses through direct modulation of T cell function *via* production of IDO. Given the pivotal role of IDO-derived metabolites from DCs in modulating immune responses in the airways \[[@R21], [@R61]--[@R64]\] and the evidence pointing to a key role of EC-derived cytokines in modulating DC behavior \[[@R54]\], it would be interesting to study the effect of the IDO pathway on the cross-talk between DCs and ECs in the context of inflammatory conditions affecting the airways. This would help to better understand several airway-related pathologies such as allergic asthma and respiratory infections, leading to the development of improved therapeutic strategies to combat deleterious inflammatory responses in the airways.

MATERIALS AND METHODS {#s4}
=====================

Lung epithelial cells {#s4_1}
---------------------

Calu-3 cells (ATCC^®^ HTB55™, a human lung epithelial adenocarcinoma cell line) were maintained in DMEM-Ham\'s Nutrient Mixture F-12 (DMEM-F12; Sigma-Aldrich, St. Louis, MO, USA) containing 10% v/v heat-inactivated FBS, 100 U/ml penicillin-100 μg/ml streptomycin (1% v/v pen/strep), 2 mM l-glutamine, and 1% v/v non-essential amino acid solution (Sigma-Aldrich, St. Louis, MO, USA). BEAS-2B cells (ATTC^®^ CRL-9609^TM^, a human bronchial epithelial cell line) were maintained in DMEM (Sigma-Aldrich, St. Louis, MO, USA) with 10% v/v heat-inactivated FBS, 100 U/ml penicillin-100 μg/ml streptomycin, and 2 mM l-glutamine. Primary human bronchial ECs were separated from the bronchial brushings (from healthy volunteers attending Nottingham University Hospital Respiratory Clinic after ethics committee approval and obtaining informed written consent) and were maintained in basal Bronchial Epithelial Growth Media supplemented with BEGM™ SingleQuots™ Kit (Clonetics™ Airway Epithelial Cell Systems, Lonza).

PBMCs separation {#s4_2}
----------------

PBMCs were isolated from fresh blood samples of healthy volunteers (obtained after receiving informed consent and local Ethics Committee approval) by density-gradient centrifugation on Histopaque (Sigma-Aldrich, St. Louis, MO, USA). The cells were washed twice with PBS and 8 × 10^5^ cells/600 μl were co-cultured with Calu-3 cells in co-culture complete medium (1:1 ratio of DMEM-F12:RPMI-1640; Sigma-Aldrich, St. Louis, MO, USA).

IDO enzymatic activity assay {#s4_3}
----------------------------

Calu-3 cells (2 × 10^5^ cells/ml) were seeded in a 24-well plate supplemented with 100 μM l-TRP (Sigma-Aldrich, St. Louis, MO, USA), and grown to confluence for 24 h. Cells were stimulated with various TLR agonists and allergen extracts, including LPS and polyribocytidylic acid (polyI:C) (both from Sigma-Aldrich, St. Louis, MO, USA), synthetic lipoprotein of *Mycoplasma salivarium* (FSL-1), CpG-ODN2216 (5′-ggGGGACGA:TCGTCgggggg-3′) (both from Invivogen), house dust mite (Greer laboratories) extract and its purified allergen (Der p 1, Indoor Biotechnologies), Bermuda grass pollen, peanut, and German cockroach extracts (all from Greer laboratories). IDO activity was measured by quantification of kynurenines in the culture supernatant using a colorimetric assay as we have described previously \[[@R64]\].

Viability assay {#s4_4}
---------------

Cell viability was quantified using the LIVE/DEAD viability/cytotoxicity kit and AlamarBlue assay (both from Invitrogen) as described previously \[[@R65], [@R66]\].

mRNA isolation, cDNA synthesis and PCR {#s4_5}
--------------------------------------

mRNA isolation and cDNA synthesis were performed using the μMACS one-step cDNA kit (Miltenyi Biotech) following the manufacturer instructions. PCR was carried out in a TC-312 PCR Thermocycler (Bibby Scientific Ltd.) using the Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific). *IDO1* specific mRNA expression was quantified relative to glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression using the following primers (Eurofins): *GAPDH* Forward (5′-GAGTCAACGGATTTGGTCGT-3′), *GAPDH* Reverse (5′-GACAAGCTTCCCGTTCTCAG-3′), *IDO1* Forward (5′-ACAGACCACAAGTCACAGCG-3′) and *IDO1* Reverse (5′-AACTGAGCAGCATGTCCTCC-3′). PCR products were analyzed on a 2% agarose gel electrophoresis system (Invitrogen, UK), visualized under UV light (Alpha Innotech Corporation), and the molecular weights of the bands were estimated with a standard 100-bp Directload DNA ladder (Sigma-Aldrich, St. Louis, MO, USA).

Western blotting {#s4_6}
----------------

Cells were washed with ice-cold PBS and then lysed using ice-cold radio-immunoprecipitation assay lysis buffer with protease and phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO, USA) on a shaker for 30 min at 4°C. Subsequently, cell lysates were centrifuged at 13,000 rpm for 30 min at 4°C. Supernatants were collected and stored at −20°C. Protein concentration was determined using the DC Protein Assay (Biorad) following the manufacturer\'s protocol. The cell lysate was electrophoresed under reducing and denaturating conditions on a pre-cast 4-15% SDS-polyacrylamide gel (Biorad), and proteins were transferred to a nitrocellulose membrane (GE Healthcare). After a 2 h incubation in blocking buffer (5% non-fat milk in Tris-glycine buffer and 0.1% Tween 20), membranes were incubated with a primary rabbit monoclonal antibody \[EPR1230Y\] to IDO (Abcam, Cambridge, UK) overnight. After washing, the secondary peroxidase-conjugated antibody (goat anti-rabbit HRP) was added for 1 h. IDO was visualized using Amersham ECL prime Western Blotting Detection Reagents (GE Healthcare). GAPDH was used as a loading control with the rabbit monoclonal antibody (Abcam, Cambridge, UK).

Gene silencing {#s4_7}
--------------

Calu-3 cells were transfected with *IDO1*-specific siRNA (GE Healthcare, UK) according to the manufacturer instructions. In brief, the cells were transfected on day one with 50 nM of *IDO1* siRNA using a non-targeting siRNA as a negative control. The cells were then incubated for 6 h in complete medium without penicillin/streptomycin in a low-attachment tissue culture plate (Corning Life Sciences, Tewksbury, MA, USA) and then left for three days. The efficiency of IDO down-regulation was assessed by an IDO activity quantitative assay as well as with conventional PCR for determination of *IDO1* mRNA expression.

Co-culture conditions {#s4_8}
---------------------

Control or IDO^low^-ECs (6 × 10^5^ cells/ml) were cultured in Transwells^®^ with a 0.4 μm pore size (Scientific Laboratory Supplies Ltd.). After reaching confluence, PBMCs (8 × 10^5^ cells/600 μl) were cultured in the bottom chamber in the presence of immobilized anti-CD3 antibody (2 μg/ml) (Sigma-Aldrich, St. Louis, MO, USA) or 5 μg/ml of tuberculin purified protein derivate (Statens Serum Institute). In some experiments, the ECs were stimulated with TLR ligands. In addition, under certain conditions, IDO metabolites (KYN, 3-HAA and its vehicle) and HCl (all from Sigma-Aldrich, St. Louis, MO, USA) were added to the PBMCs. The cells were collected after 3-6 days for a BrdU proliferation assay and the supernatants were stored for cytokine analysis.

Proliferation assay {#s4_9}
-------------------

Cell proliferation was determined with the BrdU-ELISA assay (Calbiochem, USA) according to the manufacturer instructions.

Cytokine measurements {#s4_10}
---------------------

Cytokine concentrations in the culture supernatants incubated for 24 h and 48 h were assessed using the DuoSet ELISA system for human IFN-γ (R&D Systems, UK) following the manufacturer instructions.

Statistical analysis {#s4_11}
--------------------

Data are expressed as mean values ± SEM. Statistical differences were determined using the Student *t*-test to compare two groups and using one-way ANOVA to compare three groups or more. Statistical significance was associated with *p* values \< 0.05.
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